We are live on ! Find out more
LSTA icon

Lisata Therapeutics
LSTA

25 hedge funds and large institutions have $2.13M invested in Lisata Therapeutics in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more capital invested

Capital invested by funds: $1.9M → $2.13M (+$226K)

0% less ownership

Funds ownership: 0.54% → 0.53% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

4% less funds holding

Funds holding: 26 → 25 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Holders
25
Holders Change
-1
Holders Change %
-3.85%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
3
Closed
5
Calls
$50K
Puts
–
Net Calls
+$50K
Net Calls Change
-$18K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$94.2K
2
STA
Summit Trail Advisors
New York
+$45.9K
3
Renaissance Technologies
Renaissance Technologies
New York
+$29.8K
4
Victory Capital Management
Victory Capital Management
Texas
+$4.24K
5
BlackRock
BlackRock
New York
+$1.09K

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$76.9K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$38K
3
VF
Virtu Financial
New York
-$26K
4
PAM
Panagora Asset Management
Massachusetts
-$21K
5
TRCT
Tower Research Capital (TRC)
New York
-$8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$1.01M +$29.8K +767 +3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$618K +$94.2K +2,423 +17%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$117K – – –
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$96K – – –
Deutsche Bank
5
Deutsche Bank
Germany
$79K -$76.9K -1,979 -49%
BlackRock
6
BlackRock
New York
$76K +$1.09K +28 +1%
STA
7
Summit Trail Advisors
New York
$46K +$45.9K +1,182 New
Creative Planning
8
Creative Planning
Kansas
$26K – – –
WB
9
WesBanco Bank
West Virginia
$26K – – –
LTFS
10
Ladenburg Thalmann Financial Services
Florida
$9K – – –
Morgan Stanley
11
Morgan Stanley
New York
$6K -$6.8K -175 -55%
Victory Capital Management
12
Victory Capital Management
Texas
$4K +$4.24K +109 New
Fifth Third Bancorp
13
Fifth Third Bancorp
Ohio
$3K – – –
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$3K – – –
Bank of America
15
Bank of America
North Carolina
$2K -$1.28K -33 -38%
Citigroup
16
Citigroup
New York
$1K – – –
Northwestern Mutual Wealth Management
17
Northwestern Mutual Wealth Management
Wisconsin
$1K – – –
RCAG
18
Rehmann Capital Advisory Group
Michigan
$28 – – –
KFS
19
Kelly Financial Services
Massachusetts
$26 – – –
RE
20
RBC Europe
United Kingdom
$26 – – –
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
– -$38K -1,095 Closed
VF
22
Virtu Financial
New York
– -$26K -775 Closed
PAM
23
Panagora Asset Management
Massachusetts
– -$21K -600 Closed
TRCT
24
Tower Research Capital (TRC)
New York
– -$8K -234 Closed
VNA
25
Valley National Advisers
Pennsylvania
– +$117 +3 New
1
2

LSTA Hedge Fund Activity: Q3 2019 in Review

25 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q3 2019, worth a combined $2.13M — up 12% from $1.9M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of LSTA and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.

The largest buyer was Vanguard Group, adding an estimated $94.2K. The largest seller was Deutsche Bank, cutting an estimated $76.9K.

  • 25 institutional investors held Lisata Therapeutics (LSTA) as of Q3 2019, down from 26 in Q2 2019.
  • Funds reported $2.13M of Lisata Therapeutics stock for Q3 2019, up 12% quarter-over-quarter.
  • 4 funds opened new Lisata Therapeutics positions in Q3 2019 and 5 closed out, a net change of -1 holder.
  • The largest Lisata Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $94.2K added.
  • The largest Lisata Therapeutics seller in Q3 2019 was Deutsche Bank, an estimated $76.9K sold.

Based on aggregated 13F filings for Q3 2019.